Τόμος 29 (2011) – Τεύχος 3 – Άρθρο 2 – Επιθεώρηση Κλινικής Φαρμακολογίας και Φαρμακοκινητικής-Ελληνική Έκδοση – Volume 29 (2011) – Issue 3 – Article 2 – Epitheorese Klinikes Farmakologias και Farmakokinetikes-Greek Edition

Iωάννης Τσαβδαρίδης και Μαρία Μυρωνίδου-Τζουβελέκη

Α’ Εργαστήριο Φαρμακολογίας, Ιατρική σχολή, Αριστοτέλειο Πανεπιστήμιο, Θεσσαλονίκη, Ελλάς

Ioannis Tsavdaridis and Maria Mironidou-Tzouveleki

A’ Laboratory of Pharmacology, Medical School, Aristotle University, Thessaloniki, Greece

2. Gross J.L., De Azevedo M.J., Silveiro S.P., et al.: Diabetic Nephropathy: Diagnosis, Prevention, and Treatment. Diabetes Care 28: 176-188 (2005)

3. US Renal Data System: USRDS 2010 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Available at: http://www.usrds.org/2010/pdf/v2_02.pdf

4. Chaturvedi N., Bandinelli S., Mangili R., Penno G., Rottiers R.E., Fuller J.H.: Microalbuminuria in type 1 dia-betes: rates, risk factors and glycemic threshold. Kidney Int. 60: 219-227 (2001)

5. Hovind P., Tarnow L., Rossing P., et al.: Predictors of the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 328: 1105-1108 (2004)

6. Wong T.Y., Shankar A., Klein R., Klein B.E.: Retinal vessel diameters and the incidence of gross proteinuria and renal insufficiency in people with type 1 diabetes. Diabetes 53: 179-184 (2004)

7. Giorgino F., Laviola L., Cavallo Perin P., et al.: Factors associated with progression to macroalbuminuria in micro-albuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia 47: 1020-1028 (2004)

8. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.R.: Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 63: 225-232 (2003)

9. Murussi M., Baglio P., Gross J.L., Silveiro S.P.: Risk factors for microalbuminuria and macroalbuminuria in type 2 diabetic patients: a 9-year follow-up study. Diabetes Care 25: 1101-1103 (2002)

10. Forsblom C.M., Groop P.H., Ekstrand A., et al.: Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM. Diabetes Care 21: 1932-1938 (1998)

11. Bryson C.L., Ross H.J., Boyko E.J., Young B.A.: Racial and ethnic variations in albuminuria in the US Third National Health and Nutrition Examination Survey (NHANES III) population: associations with diabetes and level of CKD. Am. J. Kidney Dis. 48: 720-726 (2006)

12. Gruden G., Viberti. G.: Pathogenesis of Diabetic Nephropathy. In: (Kahn C.R., Weir G.C., King G.L., Moses A.C., Smith R.J., Jacobson A.M., eds) Diabetes Mellitus. 14th ed., pp. 853-866, Lippincott Williams & Wilkins, Joslin’s, 2004

13. Dronavalli S., Duka I., Bakris G.L.: The pathogenesis of diabetic nephropathy. Nat. Clin. Pract. Endocrinol. Metab. 4: 444-452 (2008)

14. Cooper M.E.: Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352: 213-219 (1998)

15. Porte D.J., Schwartz M.W.: Diabetes complications: why is glucose potentially toxic? Science 272: 699-700 (1996)

16. Makita Z., Radoff S., Rayfield E.J., et al.: Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 325: 836-842 (1991)

17. Singh A.K., Mo W., Dunea G., Arruda J.A.: Effect of glycated proteins on the matrix of glomerular epithelial cells. J. Am. Soc. Nephrol. 9: 802-810 (1998)

18. Raj D.S., Choudhury D., Welbourne T.C., Levi M.: Advanced glycation end products: a Nephrologist’s perspective. Am. J. Kidney Dis. 35: 365-380 (2000)

19. Vlassara H., Striker L.J., Teichberg S., Fuh H., Li Y.M., Steffes M.: Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc. Natl. Acad. Sci. USA 91: 11704-11708 (1994)

20. Soulis-Liparota T., Cooper M., Papazoglou D., Clarke B., Jerums G.: Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334 (1991)

21. Goldfarb S., Ziyadeh F.N., Kern E.F., Simmons D.A.: Effects of polyol-pathway inhibition and dietary myo-inositol on glomerular hemodynamic function in experimental diabetes mellitus in rats. Diabetes 40: 465-471 (1991)

22. Passariello N., Sepe J., Marrazzo G., et al.: Effect of aldose reductase inhibitor (tolrestat) on urinary albumin excretion rate and glomerular filtration rate in IDDM subjects with nephropathy. Diabetes Care 16: 789-795 (1993)

23. McCaleb M.L., Sredy J., Millen J., Ackerman D.M., Dvornik D.: Prevention of urinary albumin excretion in 6 month streptozocin-diabetic rats with the aldose reductase inhibitor tolrestat. J. Diabet. Complications 2:16-18 (1988)

24. McCaleb M.L., McKean M.L., Hohman T.C., Robison W.G.: Intervention with the aldose reductase inhibitor, tolrestat, in renal and retinal lesions of streptozotocin-diabetic rats. Diabetologia 34: 695-701 (1991)

25. Burt D.J., Gruden G., Thomas S.M., et al.: P38 mito-gen-activated protein kinase mediates hexosamine-induced TGFbeta1 mRNA expression in human mesangial cells. Diabetologia 46: 531-537 (2003)

26. Kolm-Litty V., Sauer U., Nerlich A., Lehmann R., Schleicher E.D.: High glucose-induced transforming growth factor beta1 production is mediated by the hexosamine pathway in porcine glomerular mesangial cells. J. Clin. Invest. 101: 160-169 (1998)

27. Ayo S.H., Radnik R.A., Glass W.F., et al.: Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am. J. Physiol. 260(2 Pt 2): 185-191 (1991)

28. Heilig C.W., Liu Y., England R.L., et al.: D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy. Diabetes 46: 1030-1039 (1997)

29. Mogensen C.E., Christensen C.K.: Blood pressure changes and renal function in incipient and overt diabetic nephropathy. Hypertension 7: II64-73 (1985)

30. Riser B.L., Cortes P., Zhao X., Bernstein J., Dumler F., Narins R.G.: Intraglomerular pressure and mesangial stretching stimulate extracellular matrix formation in the rat. J. Clin. Invest. 90: 1932-1943 (1992)

31. Gruden G., Zonca S., Hayward A., et al.: Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 49: 655-661 (2000)

32. Gnudi L., Viberti G., Raij L., et al.: GLUT-1 overexpression: Link between hemodynamic and metabolic factors in glomerular injury? Hypertension 42: 19-24 (2003)

33. Border W.A, Noble N.A.: Transforming growth factor beta in tissue fibrosis. N. Engl. J. Med. 331: 1286-1292 (1994)

34. Ziyadeh F.N, Han D.C.: Involvement of transforming growth factor-beta and its receptors in the pathogenesis of diabetic nephrology. Kidney Int. Suppl. 60: S7-11 (1997)

35. Ziyadeh F.N., Hoffman B.B., Han D.C., et al.: Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc. Natl. Acad. Sci. USA 97: 8015-8020 (2000)

36. Inoki K., Haneda M., Maeda S., Koya D., Kikkawa R.: TGF-beta 1 stimulates glucose uptake by enhancing GLUT1 expression in mesangial cells. Kidney Int. 55: 1704-1712 (1999)

37. Benigni A., Zoja C., Corna D., et al.: Add-on anti-TGF-beta antibody to ACE inhibitor arrests progressive diabetic nephropathy in the rat. J. Am. Soc. Nephrol. 14: 1816-1824 (2003)

38. Riser B.L., Cortes P., Heilig C., et al.: Cyclic stretching force selectively up-regulates transforming growth factor-beta isoforms in cultured rat mesangial cells. Am. J. Pathol. 148: 1915-1923 (1996)

39. Ferrara N., Davis-Smyth T.: The biology of vascular endothelial growth factor. Endocr. Rev. 18: 4-25 (1997)

40. Kanesaki Y., Suzuki D., Uehara G., et al.: Vascular endothelial growth factor gene expression is correlated with glomerular neovascularization in human diabetic nephropathy. Am. J. Kidney Dis. 45: 288-294 (2005)

41. Kim N.H., Jung H.H., Cha D.R., Choi D.S.: Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J. Endocrinol. 155: 617-624 (2000)

42. Flyvbjerg A., Dagnaes-Hansen F., De Vriese A.S., Schrijvers B.F., Tilton R.G., Rasch R.: Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094 (2002)

43. Eremina V., Cui S., Gerber H., et al.: Vascular endothelial growth factor a signaling in the podocyte-endothelial compartment is required for mesangial cell migration and survival. J. Am. Soc. Nephrol. 17: 724-735 (2006)

44. Mironidou-Tzouveleki M., Tsartsalis S., Tomos C.: Vascular endothelial growth factor (VEGF) in the pathogenesis of diabetic nephropathy of type 1 diabetes mellitus. Curr. Drug Targets 21: 107-14 (2011)

45. Bortoloso E., Del Prete D., Dalla Vestra M., et al.: Quantitave and qualitative changes in vascular endothelial growth factor gene expression in glomeruli of patients with type 2 diabetes. Eur. J. Endocrinol. 150: 799-807 (2004)

46. Goldschmeding R., Aten J., Ito Y., Blom I., Rabelink T., Weening J.J.: Connective tissue growth factor: just another factor in renal fibrosis? Nephrol. Dial. Transplant. 15: 296-299 (2000)

47. Wahab N.A., Yevdokimova N., Weston B.S., et al.: Role of connective tissue growth factor in the pathogenesis of diabetic nephropathy. Biochem. J. 359: 77-87 (2001)

48. Flyvbjerg A.: Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43: 1205-1223 (2000)

49. Giordano M., DeFronzo R.A.: Acute effect of human recombinant insulin-like growth factor I on renal function in humans. Nephron 71: 10-15 (1995)

50. Koya D., King G.L.: Protein kinase C activation and the development of diabetic complications. Diabetes 47: 859-866 (1998)

51. Haneda M., Kikkawa R., Sugimoto T., et al.: Abnormalities in protein kinase C and MAP kinase cascade in mesangial cells cultured under high glucose conditions. J. Diabetes Complications 9: 246-248 (1995)

52. Ishii H., Jirousek M.R., Koya D., et al.: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 5262: 728-731 (1996)

53. Koya D., Haneda M., Nakagawa H., et al.: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J. 14: 439-447 (2000)

54. Seger R., Krebs E.G.: The MAPK signaling cascade. FASEB J. 9: 726-735 (1995)

55. Haneda M., Araki S., Togawa M., Sugimoto T., Isono M., Kikkawa R.: Mitogen-activated protein kinase cascade is activated in glomeruli of diabetic rats and glomerular mesangial cells cultured under high glucose conditions. Diabetes 46: 847-853 (1997)

56. Navarro-González J.F., Mora-Fernández C.: The role of inflammatory cytokines in diabetic nephropathy. J. Am. Soc. Nephrol. 19: 433-442 (2008)

57. DiPetrillo K., Coutermarsh B., Gesek F.A.: Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am. J. Physiol. Renal Physiol. 284: F113-121 (2003)

58. Imig J.D.: Eicosanoids and renal vascular function in diseases. Clin. Sci. (Lond) 111: 21-34 (2006)

59. Hao C.M., Breyer M.D.: Physiologic and pathophysiologic roles of lipid mediators in the kidney. Kidney Int. 70: 1105-1115 (2007)

60. Vasavada N., Agarwal R.: Role of oxidative stress in diabetic nephropathy. Adv. Chronic Kidney Dis. 12: 146-54 (2005)

61. Benigni A., Gagliardini E., Tomasoni S., et al.: Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney Int. 65: 2193-2200 (2004)

62. Langham R.G., Kelly D.J., Cox A.J., et al.: Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45: 1572-1576 (2002)

63. Doublier S., Salvidio G., Lupia E. et al.: Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 52: 1023-1030 (2003)

64. Wilson D.M., Luetscher J.A.: Plasma prorenin activity and complications in children with insulin-dependent diabetes mellitus. N. Engl. J. Med. 323: 1101-1106 (1990)

65. Daneman D., Crompton C.H., Balfe J.W., et al.: Plasma prorenin as an early marker of nephropathy in diabetic (IDDM) adolescents. Kidney Int. 46: 1154-1159 (1994)

66. Takahashi H., Ichihara A., Kaneshiro Y., et al.: Regression of nephropathy developed in diabetes by (Pro)renin receptor blockade. J. Am. Soc. Nephrol. 18: 2054-2061 (2007)

67. Εθνικό συνταγολόγιο: ΕΟΦ, σελ 109-112, Αθήνα, 2007

68. Ruggenenti P., Cravedi P., Remuzzi G.: The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat. Rev. Nephrol. 6: 319-330 (2010)

69. Wolf G., Ziyadeh F.N.: The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am. J. Kidney Dis. 29: 153-63 (1997)

70. Leehey D.J., Singh A.K., Alavi N., Singh R.: Role of angiotensin II in diabetic nephropathy. Kidney Int. Suppl. 77: S93-98 (2000)

71. Kaschina E., Unger T.: Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 12: 70-88 (2003)

72. Morgan T.: Renin, angiotensin, sodium and organ damage. Hypertens. Res. 26: 349-354 (2003)

73. Cooper M.E.: The role of the renin-angiotensin-aldosterone system in diabetes and its vascular complications. Am. J. Hypertens. 17(11Pt2): 16S-20S (2004)

74. Carey R.M., Siragy H.M.: Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr. Rev. 24: 261-271 (2003)

75. Reudelhuber T.L.: The continuing saga of the AT2 receptor: a case of the good, the bad, and the innocuous. Hypertension 46: 1261-1262 (2005)

76. Kagami S., Border W.A., Miller D.E., Noble N.A.: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J. Clin. Invest. 93: 2431-2437 (1994)

77. Lapinski R., Perico N., Remuzzi A., Sangalli F., Benigni A., Remuzzi G.: Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney. J. Am. Soc. Nephrol. 7: 653-760 (1996)